US · ENTA
Enanta Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Watertown, MA 02472
- Website
- enanta.com
Price · as of 2025-09-30
$14.35
Market cap 332M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $41.29 | +187.74% |
| Intrinsic Value(DCF) | $5.84 | -59.3% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $13.35 | $14.67 | |||
| 2013 | $27.72 | $107.97 | $10.41 | $16.20 | $0.00 |
| 2014 | $47.40 | $58.19 | $36.24 | $17.48 | $103.19 |
| 2015 | $30.02 | $104.39 | $2.56 | $33.80 | $993.38 |
| 2016 | $33.03 | $82.20 | $7.81 | $19.98 | $0.00 |
| 2017 | $48.40 | $56.80 | $18.96 | $20.47 | $22.12 |
| 2018 | $73.03 | $106.67 | $534.46 | $36.49 | $364.97 |
| 2019 | $64.08 | $90.33 | $195.78 | $35.46 | $17.90 |
| 2020 | $41.44 | $97.65 | $13.87 | $13.78 | $55.35 |
| 2021 | $69.88 | $769.82 | $6.83 | $0.22 | $46.08 |
| 2022 | $41.70 | $27.41 | $3.31 | $0.00 | $15.26 |
| 2023 | $9.25 | $13.27 | $1.98 | $0.00 | $0.00 |
| 2024 | $8.00 | $18.24 | $0.00 | $0.00 | $32.00 |
| 2025 | $14.60 | $41.29 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Enanta Pharmaceuticals, Inc.'s (ENTA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $41.29
- Current price
- $14.35
- AI upside
- +187.74%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.84
-59.3% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ENTA | Enanta Pharmaceuticals, I… | $14.35 | 332M | +188% | -59% | — | — | -3.80 | 4.81 | 4.77 | -4.57 | — | 4.81 | 92.98% | -130.65% | -125.36% | -84.63% | -91.13% | -24.91% | 3.11 | -11.11 | 4.21 | 4.03 | -2.38 | -2993.00% | -342.00% | -6674.00% | -10.33% | -0.40 | -35.04% | 0.00% | 0.00% | 6.44% | -3.79 | -10.06 | 4.96 | -1.26 |
| ASMB | Assembly Biosciences, Inc… | $29.84 | 256.95M | +2,630% | +9,923% | — | — | -1.66 | 2.00 | 2.34 | 0.93 | — | 2.00 | 100.00% | -159.26% | -140.87% | -107.92% | 55.92% | -31.39% | 0.09 | — | 2.42 | 2.35 | 0.78 | -5000.00% | 29816.00% | -32743.00% | -76.60% | -1.07 | 62.97% | 0.00% | 0.00% | 26.59% | 0.93 | 0.83 | -1.48 | -9.57 |
| AVIR | Atea Pharmaceuticals, Inc… | $4.68 | 365.63M | — | — | — | — | -1.50 | 0.57 | — | 1.53 | -6.59 | 0.57 | 0.00% | — | — | -33.88% | 1111.34% | -31.78% | 0.00 | — | 24.85 | 24.44 | 0.48 | 2270.00% | — | 5867.00% | -53.78% | -7.28 | 780.43% | 0.00% | 0.00% | 0.00% | 1.04 | 1.48 | — | 4.54 |
| CRBU | Caribou Biosciences, Inc. | $1.90 | 177.59M | +1,241% | -57% | — | +5,094% | -0.70 | 0.41 | 10.48 | 0.48 | -3.59 | 0.41 | 60.71% | -1667.16% | -1491.95% | -47.99% | -243.96% | -40.00% | 0.10 | — | 7.16 | 6.94 | -0.06 | 1957.00% | -7101.00% | 3794.00% | -138.12% | -4.51 | -211.89% | 0.00% | 0.00% | 0.00% | 0.47 | 0.54 | -7.83 | -1.96 |
| FHTX | Foghorn Therapeutics Inc. | $5.68 | 332.74M | +360% | -68% | — | +572% | -2.86 | -5.45 | 10.98 | -0.43 | — | -5.45 | 100.00% | -454.31% | -383.24% | 141.17% | 39.62% | -30.40% | -0.82 | — | 3.73 | 3.64 | 0.19 | -3248.00% | -3383.00% | -1510.00% | -40.83% | -1.50 | 39.09% | 0.00% | 0.00% | 0.00% | -0.40 | -0.41 | 1.84 | -2.64 |
| IMRX | Immuneering Corporation | $4.99 | 181.15M | — | — | — | — | -0.75 | 1.10 | — | -0.21 | -8.77 | 1.33 | 0.00% | — | — | -92.51% | -682.42% | -78.61% | 0.10 | — | 5.28 | 4.82 | 0.50 | 851.00% | — | 1171.00% | -120.87% | -7.33 | -586.70% | 0.00% | 0.00% | 0.00% | -0.21 | -0.25 | — | -6.82 |
| NAUT | Nautilus Biotechnology, I… | $2.42 | 305.66M | — | — | — | — | -4.96 | 1.87 | — | -4.18 | — | 1.87 | 0.00% | — | — | -32.27% | -69.30% | -27.20% | 0.19 | — | 13.33 | 13.00 | -0.34 | -1607.00% | — | -1517.00% | -17.74% | -6.38 | -53.89% | 0.00% | 0.00% | 0.05% | -3.28 | -4.22 | — | 2.18 |
| PRLD | Prelude Therapeutics Inco… | $2.76 | 210M | — | — | — | — | -0.44 | 0.42 | 7.97 | 0.43 | — | 0.42 | 100.00% | -1995.91% | -1816.76% | -69.01% | -756.99% | -56.12% | 0.14 | — | 5.30 | 5.21 | -0.04 | -1683.00% | — | -626.00% | -185.78% | -4.01 | -561.60% | 0.00% | 0.00% | 0.00% | 0.43 | 0.58 | -8.54 | -5.73 |
| PYXS | Pyxis Oncology, Inc. | $1.47 | 91.53M | — | — | — | — | -0.88 | 0.56 | 4.20 | 0.59 | — | 0.57 | 97.06% | -554.07% | -478.95% | -62.75% | -416.82% | -46.74% | 0.17 | — | 7.49 | 7.18 | -0.01 | -2865.00% | — | -2522.00% | -85.42% | -3.26 | -277.36% | 0.00% | 0.00% | 16.14% | 0.44 | 0.67 | -2.41 | -3.02 |
| TNYA | Tenaya Therapeutics, Inc. | $0.56 | 93.6M | — | — | — | — | -0.35 | 0.42 | — | 0.09 | — | 0.42 | 0.00% | — | — | -95.69% | -251.45% | -76.52% | 0.15 | — | 4.22 | 3.85 | -0.09 | -2202.00% | — | -1141.00% | -237.15% | -5.67 | -198.49% | 0.00% | 0.00% | 0.00% | 0.08 | 0.10 | — | -7.83 |
| VYGR | Voyager Therapeutics, Inc… | $4.10 | 227.96M | +883% | -19% | — | +1,465% | -3.78 | 0.82 | 3.07 | -0.29 | — | 0.82 | 100.00% | -104.11% | -81.25% | -24.25% | -162.45% | -17.47% | 0.15 | — | 5.56 | 5.45 | 0.35 | -13805.00% | -6800.00% | -12522.00% | -7.67% | -0.31 | -36.73% | 0.00% | 0.00% | 0.00% | -0.27 | -1.21 | 0.28 | 0.62 |
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
- CEO
- Jay R. Luly
- Employees
- 131
- Beta
- 0.99
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.84 ÷ $14.35) − 1 = -59.3% (DCF, example).